Follicular lymphoma: an update on biology and optimal therapy

References

• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;01;107(1):265–276.
   Web of Science ®Google Scholar
• Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;11;116(19):3724–3734.
   Web of Science ®Google Scholar
• Smith A, Crouch S, Lax S, et al. Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the Uk’s haematological malignancy research network. Br J Cancer. 2015;28;112(9):1575–1584.
   Web of Science ®Google Scholar
• Teras LR, DeSantis CE, Cerhan JR, et al. US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443–459.
   PubMed Web of Science ®Google Scholar
• Cerhan JR. Epidemiology of follicular lymphoma. Hematol Oncol Clin North Am. 2020;34(4):631–646.
   PubMed Web of Science ®Google Scholar
• Goldin LR, Björkholm M, Kristinsson SY, et al. Highly increased familial risks for specific lymphoma subtypes. Br J Haematol. 2009;146(1):91–94.
   PubMed Web of Science ®Google Scholar
• Linet MS, Vajdic CM, Morton LM, et al. Medical history, lifestyle, family history, and occupational risk factors for follicular lymphoma: the interlymph non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014;2014(48):26–40.
   PubMedGoogle Scholar
• Morton LM, Slager SL, Cerhan JR, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the interlymph non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014;2014(48):130–144.
   PubMedGoogle Scholar
• Leich E, Hoster E, Wartenberg M, et al. Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus. Leukemia. 2016;30(4):854–860.
   PubMed Web of Science ®Google Scholar
• Yunis JJ, Oken MM, Kaplan ME, et al. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin’s lymphoma. N Engl J Med. 1982;307(20):1231–1236.
   PubMed Web of Science ®Google Scholar
• Hockenbery D, Nuñez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348(6299):334–336.
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226(4678):1097–1099.
   PubMed Web of Science ®Google Scholar
• Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol. 2012;30:429–457.
   PubMed Web of Science ®Google Scholar
• Egle A, Harris AW, Bath ML, et al. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood. 2004;103(6):2276–2283.
   PubMed Web of Science ®Google Scholar
• Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest. 2012;122(10):3424–3431.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298–303.
   PubMed Web of Science ®Google Scholar
• Green MR, Kihira S, Liu CL, et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci USA. 2015;112(10):E1116–E1125.
   PubMed Web of Science ®Google Scholar
• Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111–1122.
   PubMed Web of Science ®Google Scholar
• Okosun J, Bödör C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46(2):176–181.
   PubMed Web of Science ®Google Scholar
• Green MR, Gentles AJ, Nair RV, et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood. 2013;121(9):1604–1611.
   PubMed Web of Science ®Google Scholar
• Limpens J, Stad R, Vos C, et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood. 1995;85(9):2528–2536.
   PubMed Web of Science ®Google Scholar
• Schüler F, Dölken L, Hirt C, et al. Prevalence and frequency of circulating t(14;18)-MBR translocation carrying cells in healthy individuals. Int J Cancer. 2009;124(4):958–963.
   PubMed Web of Science ®Google Scholar
• Roulland S, Kelly RS, Morgado E, et al. Translocation: a predictive blood biomarker for follicular lymphoma. J Clin Oncol. 2014;32(13):1347–1355.
   PubMed Web of Science ®Google Scholar
• Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014;14(8):517–534.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Novak AJ, Ziesmer SC, et al. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin’s lymphoma. Cancer Res. 2009;69(13):5522–5530.
   PubMed Web of Science ®Google Scholar
• Carbone A, Roulland S, Gloghini A, et al. Follicular lymphoma. Nat Rev Dis Primers. 2019;12;5(1):83.
   Google Scholar
• Staiger AM, Hoster E, Jurinovic V, et al. Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles. Blood. 2020;135(3):181–190.
   PubMed Web of Science ®Google Scholar
• WHO. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Swerdlow SH, Campo E, Harris NL, et al. editors. Lyon: International Agency for Research on Cancer; 2017.
   Google Scholar
• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748.
   PubMed Web of Science ®Google Scholar
• Leich E, Ott G, Rosenwald A. Pathology, pathogenesis and molecular genetics of follicular NHL. Best Pract Res Clin Haematol. 2011;24(2):95–109.
   PubMed Web of Science ®Google Scholar
• Randall C, Fedoriw Y. Pathology and diagnosis of follicular lymphoma and related entities. Pathology. 2020;52(1):30–39.
   PubMed Web of Science ®Google Scholar
• Campo E, Jaffe ES, Cook JR, et al. The International consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140(11):1229–1253.
   PubMed Web of Science ®Google Scholar
• Ott G, Katzenberger T, Lohr A, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood. 2002;99(10):3806–3812.
   PubMed Web of Science ®Google Scholar
• Bosga-Bouwer AG, van Imhoff GW, Boonstra R, et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood. 2003;101(3):1149–1154.
   PubMed Web of Science ®Google Scholar
• Louissaint A, Jr, Ackerman AM, Dias-Santagata D, et al. Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. Blood. 2012;120(12):2395–2404.
   PubMed Web of Science ®Google Scholar
• Araf S, Fitzgibbon J. Pediatric-type FL: simply different. Blood. 2016;128(8):1030–1031.
   PubMed Web of Science ®Google Scholar
• Louissaint A, Jr, Schafernak KT, Geyer JT, et al. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. Blood. 2016;128(8):1093–1100.
   PubMed Web of Science ®Google Scholar
• Schmidt J, Gong S, Marafioti T, et al. Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood. 2016;128(8):1101–1111.
   PubMed Web of Science ®Google Scholar
• Attarbaschi A, Beishuizen A, Mann G, et al. Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a "watch and wait" strategy after complete resection. Ann Hematol. 2013;92(11):1537–1541.
   PubMed Web of Science ®Google Scholar
• Schmatz AI, Streubel B, Kretschmer-Chott E, et al. Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J Clin Oncol. 2011;10;29(11):1445–1451.
   Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;32(3):298–308.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Fingerle-Rowson G, Boehme A, et al. Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006–2009. Leuk Lymphoma. 2015;56(3):694–702.
   PubMed Web of Science ®Google Scholar
• Dinnessen MAW, van der Poel MWM, Tonino SH, et al. Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in The Netherlands, 1989–2016. Leukemia. 2021;35(6):1683–1695.
   PubMed Web of Science ®Google Scholar
• Alig S, Jurinovic V, Shahrokh Esfahani M, et al. Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models. Blood Adv. 2020;4(18):4451–4462.
   PubMed Web of Science ®Google Scholar
• Bachy E, Houot R, Morschhauser F, et al. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica. 2013;98(7):1107–1114.
   PubMed Web of Science ®Google Scholar
• Bachy E, Seymour JF, Feugier P, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol. 2019;37(31):2815–2824.
   PubMed Web of Science ®Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study. J Clin Oncol. 2015;10;33(23):2516–2522.
   Web of Science ®Google Scholar
• Jurinovic V, Kridel R, Staiger AM, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016;128(8):1112–1120.
   PubMed Web of Science ®Google Scholar
• Wagner-Johnston ND, Link BK, Byrtek M, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the national Lympho Care study (NLCS). Blood. 2015;126(7):851–857.
   PubMed Web of Science ®Google Scholar
• Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the university of Iowa/MayoClinic specialized program of research excellence molecular epidemiology resource. J Clin Oncol. 2013;31(26):3272–3278.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Trneny M, Xerri L, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34(22):2575–2582.
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;1;104(5):1258–1265.
   PubMed Web of Science ®Google Scholar
• Bachy E, Maurer MJ, Habermann TM, et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018;132(1):49–58.
   PubMed Web of Science ®Google Scholar
• Buske C, Hoster E, Dreyling M, et al. The Follicular lymphoma international prognostic index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108(5):1504–1508.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–4562.
   PubMed Web of Science ®Google Scholar
• Huet S, Tesson B, Jais JP, et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 2018;19(4):549–561.
   PubMed Web of Science ®Google Scholar
• Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331–1344.
   PubMed Web of Science ®Google Scholar
• Casulo C, Dixon JG, Le-Rademacher J, et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;17;139(11):1684–1693.
   Google Scholar
• Sortais C, Lok A, Tessoulin B, et al. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life. Ann Hematol. 2020;99(7):1595–1604.
   PubMed Web of Science ®Google Scholar
• Tobin JWD, Keane C, Gunawardana J, et al. Progression of disease within 24 months in follicular lymphoma Is associated with reduced intratumoral immune infiltration. J Clin Oncol. 2019; Dec 37(34):3300–3309.
   PubMed Web of Science ®Google Scholar
• Luminari S, Biasoli I, Arcaini L, et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the fondazione italiana linfomi. Ann Oncol. 2013;24(8):2108–2112.
   PubMed Web of Science ®Google Scholar
• Metser U, Dudebout J, Baetz T, et al. [18F]-FDG PET/CT in the staging and management of indolent lymphoma: a prospective multicenter PET registry study. Cancer. 2017;123(15):2860–2866.
   PubMed Web of Science ®Google Scholar
• Campbell BA, Voss N, Woods R, et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer. 2010;116(16):3797–3806.
   PubMed Web of Science ®Google Scholar
• MacManus M, Fisher R, Roos D, et al. Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03. J Clin Oncol. 2018;36(29):2918–2925.
   PubMed Web of Science ®Google Scholar
• Hadi I, Schummer A, Dreyling M, et al. Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin’s lymphoma: a monocenter analysis. Sci Rep. 2021;11(1):22586.
   PubMed Web of Science ®Google Scholar
• Brady JL, Binkley MS, Hajj C, et al. Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: a collaborative study by ILROG. Blood. 2019;133(3):237–245.
   PubMed Web of Science ®Google Scholar
• Herfarth K, Borchmann P, Schnaidt S, et al. Rituximab with involved field irradiation for early-stage nodal follicular lymphoma: results of the MIR study. Hemasphere. 2018;2(6):e160.
   PubMed Web of Science ®Google Scholar
• Stuschke M, Hoederath A, Sack H, et al. Extended field and total Central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: results of a prospective multicenter study Study Group NHL-Frühe Stadien. Cancer. 1997;80(12):2273–2284.
   Google Scholar
• Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86–92.
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Kirkwood AA, Popova B, et al. 4 Gy versus 24 gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15(4):457–463.
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the groupe d‘Etude des lymphomes folliculaires. J Clin Oncol. 1997;15(3):1110–1117.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Smith P, Norton A, British National Lymphoma Investigation, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516–522.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15(4):424–435.
   PubMed Web of Science ®Google Scholar
• Sinha R, Byrtek M, DeJoubner NJ, et al. Examining the outcomes of watchful waiting (WW) Among US patients with advanced stage follicular lymphoma (FL). Blood. 2011;118(21):775–775.
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Bellei M, Marcheselli L, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012;30(31):3848–3853.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725–3732.
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Kahl B, et al. First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019;37(12):984–991.
   PubMed Web of Science ®Google Scholar
• Townsend W, Hiddemann W, Buske C, et al. S206: obinutuzumab plus chemotherapy demonstrates long-term benefit over rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: final analysis of the gallium study. HemaSphere. 2022;6:107–108.
   Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, Study group indolent Lymphomas (StiL), et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018;36(23):2395–2404.
   PubMed Web of Science ®Google Scholar
• Buske C, Dreyling M, Alvarez-Larrán A, et al. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA interdisciplinary expert consensus. ESMO Open. 2022;7(2):100403.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379(10):934–947.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Nastoupil L, Feugier P, et al. Six-year results from the phase 3 randomized study relevance show similar outcomes for previously untreated follicular lymphoma patients receiving lenalidomide Plus rituximab (R 2) versus rituximab-chemotherapy followed By rituximab maintenance. Blood. 2021;138(Supplement 1):2417–2417.
   Google Scholar
• Bachy E, Houot R, Feugier P, et al. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study. Blood. 2022;139(15):2338–2346.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51.
   PubMed Web of Science ®Google Scholar
• Hirt C, Hoster E, Unterhalt M, et al. Rituximab maintenance versus observation after immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in untreated follicular lymphoma patients: a randomized trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German low-grade lymphoma Study Group. Hemasphere. 2021;5(7):e600.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Burke JM, van der Jagt R, et al. Assessment of maintenance rituximab after first-line bendamustine-rituximab in patients with follicular lymphoma: an analysis from the BRIGHT trial. Blood. 2017;130(Supplement 1):484–484.
   Google Scholar
• Luminari S, Nizzoli ME, Chiarenza A, et al. Impact of immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction management of treatment naïve advanced stage follicular lymphoma patients: a subset analysis of the FOLL12 trial By the fondazione italiana linfomi (FIL). Blood. 2021;138(Supplement 1):811–811.
   PubMedGoogle Scholar
• Hill BT, Nastoupil L, Winter AM, et al. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol. 2019;184(4):524–535.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Buske C, Hertenstein B, et al. Four Versus two years of rituximab maintenance (R-maintenance) Following bendamustine Plus rituximab (B-R): initial results of a prospective, randomized multicenter phase 3 study in First-Line follicular lymphoma (the StiL NHL7-2008 MAINTAIN study). Blood. 2017;130(Supplement 1):483–483.
   Google Scholar
• Kobbe G, Pechtel S, Zohren F, et al. Prognostic value of circulating bcl-2/igh levels before and after treatment in 415 patients with advanced follicular lymphoma receiving First-Line Immuno-Chemotherapy in 2 prospective StiL trials – the effect of rituximab maintenance. Blood. 2018;132(Supplement 1):4149–4149.
   Google Scholar
• Dreyling M, Aurer I, Federico M, et al. EHA/ESMO clinical practice guidelines for the management of malignant lymphoma: recommendations for the second phase of the COVID-19 pandemic. Hemasphere. 2021;5(2):e529.
   PubMed Web of Science ®Google Scholar
• Casulo C, Barr PM. How I treat early-relapsing follicular lymphoma. Blood. 2019;133(14):1540–1547.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Chua N, Mayer J, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN Study. J Clin Oncol. 2018;36(22):2259–2266.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Uddin R, Boumendil A, et al. Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial. Bone Marrow Transplant. 2021;56(6):1413–1421.
   PubMed Web of Science ®Google Scholar
• Jiménez-Ubieto A, Grande C, Caballero D, et al. Autologous stem cell transplantation for follicular lymphoma: favorable Long-Term survival irrespective of pretransplantation rituximab exposure. Biol Blood Marrow Transplant. 2017;23(10):1631–1640.
   PubMed Web of Science ®Google Scholar
• Jiménez-Ubieto A, Grande C, Caballero D, et al. Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment. Hematol Oncol. 2018;36(5):765–772.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Trneny M, Izutsu K, et al. Pf483 efficacy was improved with lenalidomide/rituximab (r2) vs rituximab/placebo in patients with follicular lymphoma irrespective of pod24 status in the phase iii augment study. HemaSphere. 2019;3(S1):193–194.
   Google Scholar
• Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide Plus rituximab Versus placebo Plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188–1199.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Le Gouill S, Feugier P, et al. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. Lancet Haematol. 2019;6(8):e429–e437.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–1018.
   PubMed Web of Science ®Google Scholar
• Salles G, Schuster SJ, de Vos S, et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica. 2017;102(4):e156–e159.
   PubMed Web of Science ®Google Scholar
• Matasar MJ, Capra M, Özcan M, et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):678–689.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433–1442.
   PubMed Web of Science ®Google Scholar
• Batlevi CL, Park SI, Phillips TJ, et al. Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma. J Clin Oncol. 2022;40(16_suppl):7572–7572.
   Web of Science ®Google Scholar
• Jurczak W, Zinzani PL, Gaidano G, et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2018;29(5):1266–1272.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Hübel K, Luminari S, et al. inMIND: a phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma. J Clin Oncol. 2022;40(16_suppl):TPS7583–TPS7583. TPS7583.
   Web of Science ®Google Scholar
• Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91–103.
   PubMed Web of Science ®Google Scholar
• Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325–332.
   PubMed Web of Science ®Google Scholar
• Budde LE, Sehn LH, Matasar MJ, et al. Mosunetuzumab Monotherapy Is an effective and Well-Tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 prior lines of therapy: pivotal results from a phase I/II study. Blood. 2021;138(Supplement 1):127–127.
   Google Scholar
• Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055–1065.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Bishton M, Eyre TA, et al. Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed/refractory follicular lymphoma: initial results from a phase ib study. Blood. 2021;138(Supplement 1):129–129.
   Google Scholar
• Nastoupil LJ, Morschhauser F, Scholz CW, et al. CELESTIMO: a phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥1 line of systemic therapy. J Clin Oncol. 2022;40(16_suppl):TPS7588–TPS7588.
   Web of Science ®Google Scholar
• Morschhauser F, Carlo-Stella C, Dickinson M, et al. Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R/R) follicular lymphoma (FL). Blood. 2021;138(Supplement 1):128–128.
   Google Scholar
• Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021;25;398(10306):1157–1169.
   Web of Science ®Google Scholar
• Leonard JP, Jung SH, Johnson J, et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (alliance). J Clin Oncol. 2015;33(31):3635–3640.
   PubMed Web of Science ®Google Scholar
• Lansigan F, Andorsky DJ, Coleman M, et al. Completed Induction phase analysis of magnify: phase 3b study of lenalidomide + rituximab (R 2) followed By maintenance in relapsed/refractory indolent non-Hodgkin lymphoma. Blood. 2021;138(Supplement 1):812–812.
   Google Scholar
• Dreyling M, Morschhauser F, Bouabdallah K, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28(9):2169–2178.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-Kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898–3905.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Santoro A, Mollica L, et al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol. 2020;95(4):362–371.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-Targeting T-Cell-Engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-Cell lymphoma: a phase I trial. J Clin Oncol. 2021;39(18):1959–1970.
   PubMed Web of Science ®Google Scholar
• Buske C, Dreyling M, Herfarth K. et al. Follikuläres Lymphom: Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. 2022; [cited 2022 April 23]. Available from: https://www.onkopedia.com/de/onkopedia/guidelines/follikulaeres-lymphom/@@guideline/html/index.html.
   Google Scholar